Journal Homepage: - www.journalijar.com

INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI: 10.21474/IJAR01/20165
DOI URL: http://dx.doi.org/10.21474/IJAR01/20165

REVIEW ARTICLE

CUTTING-EDGE DEVELOPMENTS IN HPLC FOR IDENTIFYING PROCESS IMPURITIES: A REVIEW ON METHOD OPTIMIZATION AND VALIDATION

M. Manivardhan Reddy[1], Deshoju Srinu[2], G. Sampath Kumar Reddy[3] and K. Ramadevi[4]

1. Department of Chemistry, Anurag University, Hyderabad, India.
2. Analytical Research and Development, AuroreLife Sciences Private Limited, Hyderabad, India.
3. Analytical Research and Development, AuroreLife Sciences Private Limited, Hyderabad, India.
4. Department of Pharmacy, Anurag University, Hyderabad, India.

Manuscript Info

Manuscript History
Received: 05 November 2024
Final Accepted: 09 December 2024
Published: January 2025

Key words:-
High Performance Liquid Chromatography, Genotoxic Impurities, Nitrosamines, Pharmaceutical Analysis, Method Validation, Scalability

Abstract

High-Performance Liquid Chromatography (HPLC) is a widely utilized column chromatography technique in biochemistry and analytical sciences for the separation, identification, and quantification of active compounds. Renowned as a leading separation technology, HPLC plays a pivotal role in detecting, separating, and quantifying pharmaceutical drugs. The development and validation of HPLC methods are essential in novel drug discovery, development, manufacturing, and various human and animal studies. This review highlights the comprehensive processes involved in the development and validation of HPLC methods. Method development is influenced by factors such as the chemical structure of molecules, synthetic pathways, solubility, polarity, pH, pKa values, and the activity of functional groups. Validation, as per ICH Guidelines, encompasses key parameters including accuracy, precision, specificity, linearity, range, limits of detection and quantification, robustness, and system suitability testing.

Introduction:-

High-Performance Liquid Chromatography (HPLC) is a powerful analytical method widely employed for detecting and quantifying impurities in complex mixtures. In the pharmaceutical industry, it plays a crucial role in meeting stringent regulatory standards for identifying process impurities, degradation impurities, and genotoxic impurities (GTIs) [6]. Regulatory frameworks such as ICH M7 emphasize the importance of controlling genotoxic impurities, including nitrosamines, at trace levels to ensure product safety and compliance [1]. Recent advancements underscore the critical role of HPLC in achieving regulatory compliance and fostering innovations in method development and impurity profiling. These include high-resolution columns, integration with mass spectrometry, and advanced automation, which have significantly enhanced sensitivity, precision, and throughput in impurity analysis [7,11].

Main Text

Introduction to HPLC

High-Performance Liquid Chromatography (HPLC) is an analytical technique that separates compounds based on their interactions with a stationary phase within a column and their polarity or chemical properties [11]. Since its inception, HPLC has become a cornerstone of modern analytical science due to its precision, sensitivity, and versatility [3]. It is extensively applied in pharmaceuticals, biotechnology, food safety, and environmental monitoring

Corresponding Author:- M. Manivardhan Reddy
Address:- Department of Chemistry, Anurag University, Hyderabad, India.

[11]. In pharmaceutical applications, HPLC is essential for identifying process impurities, such as process impurities, degradants, and genotoxic impurities (GTIs) [6]. The capabilities of HPLC technology have been significantly enhanced through innovations like its integration with mass spectrometry (LC-MS), enabling the identification of trace contaminants at sub-parts-per-million (ppm) levels [8]. Additionally, the introduction of advanced column technologies, such as core-shell and monolithic columns, has led to improved separation and analysis of complex mixtures, ensuring compliance with stringent regulatory standards [7].

HPLC in Addressing Analytical Challenges: Insights and Solutions
The application of HPLC in pharmaceutical and industrial quality control is not without challenges. These include:

Detection and Analysis of Genotoxic Impurities (GTIs) in Pharmaceuticals:
Substances that can damage DNA, known as genotoxic impurities, are considered potential cancer-causing agents and must be identified at extremely low concentrations, often at sub-parts-per-billion (ppb) levels [6]. Guidelines from regulatory bodies, such as ICH M7, emphasize the necessity of employing highly sensitive and precise analytical techniques like HPLC to monitor and control these impurities [1].

Approaches to Handling and Analyzing Complex Sample Matrices:
The complexity of pharmaceutical products or drug substances can lead to matrix effects that interfere with the accurate detection of GTIs. To effectively separate target compounds from complex mixtures, advanced sample preparation methods, such as solid-phase extraction (SPE) and liquid-liquid extraction (LLE), are essential in isolating analytes of interest [11].

Technological Demands:
The detection of GTIs, such as nitrosamines, requires high sensitivity and selectivity. HPLC coupled with mass spectrometry (LC-MS), especially in tandem mode (LC-MS/MS), provides unmatched capabilities for analyzing trace impurities in complex matrices [8,9].

Advanced Approaches for the Detection of Genotoxic Impurities and Nitrosamines in drug substances
Nitrosamines, a subset of GTIs, are among the most scrutinized impurities in pharmaceuticals due to their potent carcinogenicity. These compounds typically form through the reaction of nitrosating agents with secondary or tertiary amines during manufacturing or storage [2]. Notable examples include N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA), both of which are classified as probable human carcinogens [4]. The global recall of pharmaceuticals contaminated with nitrosamines has prompted stringent regulatory action. International regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have set permissible daily intake limits, necessitating advanced analytical techniques for their detection [12]. High-resolution LC-MS and LC-MS/MS have become the methods of choice, offering sensitivity at sub-parts-per-billion (ppb) levels [9]. Recent studies highlight the success of LC-MS in identifying sources of nitrosamine contamination and supporting corrective measures [8].

Method Development and Validation
The development of robust HPLC methods involves optimizing multiple parameters:
Column Selection:
In HPLC, selecting the appropriate column and stationary phase is critical for effective separation of analytes. The stationary phase interacts with the target compounds, and its polarity should align with that of the analytes. Polar analytes interact more effectively with polar stationary phases, while non-polar analytes are better separated using non-polar phases [11]. Additional factors, such as particle size and column dimensions, also influence separation efficiency. Proper column selection ensures optimal resolution, accurate retention times, and reproducible results, essential for high-quality chromatographic analysis [3].

Mobile Phase Optimization:
The selection and optimization of mobile phase components are fundamental in achieving efficient separation and detection. Buffer pH, ionic strength, and the ratio of organic to aqueous solvents must be carefully tailored to match the analytes' chemical properties and enhance resolution [7].

The validation of High-Performance Liquid Chromatography (HPLC) methods is essential for ensuring the accuracy, precision, and reproducibility of analytical results, particularly within regulated sectors such as the pharmaceutical

industry. According to the ICH Q2(R1) guidelines, specific validation parameters must be addressed, including linearity, which evaluates the method's capacity to produce consistent results across a range of concentrations, and sensitivity, which assesses the method's ability to detect trace levels of analytes [5]. Robustness testing is performed to verify the method's reliability under varied operational conditions. Adherence to these validation criteria ensures compliance with regulatory standards, thereby ensuring the integrity of analytical results and supporting product quality and safety. Furthermore, advanced methodologies such as Quality by Design (QbD) have optimized method development by incorporating risk-based strategies and statistical tools, enhancing the robustness and reliability of the HPLC approach.[1].

Optimizing HPLC Methods for Scalability in Pharmaceutical and Industrial Processes

As impurity testing often needs to be scaled up for high-throughput environments, particularly in manufacturing processes, scalable HPLC methods are essential. Automation in HPLC systems allows for continuous or batch sampling, facilitating large-scale analysis without sacrificing accuracy or precision [9]. This scalability is particularly important in the pharmaceutical industry, where large batches of APIs need to be tested for impurity levels across multiple production cycles [3]. Scaling HPLC methods from laboratory settings to industrial applications involves addressing the following:

Cost Efficiency:

Balancing analytical performance with operational costs involves optimizing consumables, such as solvents and columns, and implementing proper maintenance protocols [10].

Instrumentation Durability:

Industrial HPLC systems are designed for prolonged use, with durable columns and high-pressure pumps to ensure operational stability [11].

Automation:

The incorporation of robotic systems and autosamplers has improved throughput and consistency [8].

High-Throughput Analysis:

Techniques like multiplexed HPLC systems enable the simultaneous analysis of multiple samples, enhancing efficiency [7].

Financial Implications:

Economic factors play a crucial role in the adoption of HPLC techniques. While the initial investment in LC-MS systems is high, their sensitivity, specificity, and automation capabilities provide significant long-term benefits [5]

Cost-effectiveness analyses usually examine:

Routine Supplies:

Ongoing expenses such as mobile phase solvents and column replacements.

Automation:

Reduced labour costs through automated sample injection, mobile phase delivery, and data processing in HPLC analysis.

Adherence to Regulations:

Mitigating the risk of non-compliance with impurity limits by adhering to strict regulatory standards, which justifies the investment in advanced HPLC technologies

Outlook for the Future

The future of high-performance liquid chromatography (HPLC) in pharmaceutical analysis is set to embrace several emerging trends, driven by the need for improved efficiency, sensitivity, and cost-effectiveness in detecting process-related impurities, including genotoxic impurities such as nitrosamines [6]. As pharmaceutical manufacturing scales up, there is an increasing demand for high-throughput HPLC methods capable of identifying trace impurities in large batches [11]. Advances in HPLC technology, such as high-resolution columns and coupling with mass spectrometry (LC-MS/MS), provide enhanced sensitivity and selectivity, enabling the detection of even the smallest amounts of genotoxic compounds [8]. These developments facilitate rapid, reliable, and reproducible results, which are critical

for meeting regulatory requirements and ensuring product safety [9]. Additionally, automation and integration with software platforms streamline workflows, reducing manual intervention and saving both time and labor costs [10].
Emerging trends in HPLC include:

Artificial Intelligence (AI):
AI is increasingly being used in HPLC to enhance analytical efficiency. Machine learning algorithms optimize chromatographic conditions, adjusting parameters such as flow rate and gradient profiles for better performance. Additionally, AI aids in interpreting complex datasets, improving data accuracy, and accelerating analysis, which supports more informed decision-making [3].

Portable HPLC Systems:
Portable HPLC systems offer significant advantages for on-site quality control and rapid impurity testing. Miniaturized HPLC devices enable real-time analysis of active pharmaceutical ingredients (APIs) and excipients at manufacturing sites, ensuring regulatory compliance and immediate contaminant identification [7].

Advanced Detectors and Sampling Devices:
Innovations in sampling methods, such as solid-phase microextraction (SPME) and needle-based devices, enhance sensitivity, accuracy, and applicability in pharmaceutical analysis [11].

Sustainable Practices:
The adoption of hydrogen as a mobile phase modifier and the development of eco-friendly stationary phases align with green chemistry principles [8].

Integrated Analytical Platforms:
Combining HPLC with techniques such as liquid chromatography (LC) or spectroscopy enables a more comprehensive analysis of complex samples [6].

Conclusions:-

High-performance liquid chromatography (HPLC) is evolving to address the increasing complexities of impurity analysis in the pharmaceutical industry, with notable advancements in automation, miniaturization, and sustainability.

The integration of AI-driven analytics is transforming data interpretation, enabling faster, more accurate results while minimizing human error. Furthermore, progress in miniaturization is enhancing the accessibility and efficiency of HPLC systems, making them more cost-effective and user-friendly. Sustainable practices, such as the use of hydrogen as a mobile phase modifier and the development of eco-friendly stationary phases, align with green chemistry principles, promoting a more environmentally responsible approach. These innovations will strengthen HPLC's crucial role in ensuring product quality, regulatory compliance, and adherence to environmental standards

List of Abbreviations
HPLC: High Performance Liquid Chromatography
GTIs: Genotoxic Impurities
ICH: International Council for Harmonisation
LC-MS: Liquid Chromatography-Mass Spectrometry

Declarations

Acknowledgments:-

I would like to acknowledge Dr K.Ramadevi (Associate professor, Anurag University), who guiding me in Ph. D work**.**

I would like to acknowledge Dr G. Sampath Kumar Reddy (Head- AR&D & Quality, Aurore Life Sciences Private Limited), who encouraged and facilities to do research work**.**

I would like to acknowledge Mr J. Rajendar Rao (MD &CEO, Aurore Life Sciences Private Limited), who providing facilities to do research work**.**

Consent for acknowledgment:
I have received the permission to acknowledge from all the persons mentioned in the "Acknowledgements" section.

Consent for Publication:
All authors consent to publication.

Authors' Contributions:
Mr. M. Manivardhan Reddy collected and analysed the data and wrote the manuscript. He is the lead author and showed strong commitment to the work. Dr. G Sampath Kumar Reddy has made critical suggestions to the conception and substantively revised the work. Dr. K.Ramadevi was the supporting pillar for writing manuscript and reviewed the work. All authors have read and approved the manuscript.

Funding:
No funding.

Availability of Data and Materials:
Data sharing not applicable to this article as no data sets were generated or analysed during the current study.

Ethics Approval and Consent to Participate:
Not applicable.

Competing Interests:
The authors declare no competing interests.

Authors' details:
1) Department of Chemistry, Anurag University, Hyderabad, India.
2) Department of Analytical Research and Development, Aurore Life Sciences Private Limited, Hyderabad, India

References:-

1. European Medicines Agency [EMA]. (2006). Guideline on the limits of genotoxic impurities. https://www.ema.europa.eu
2. European Medicines Agency [EMA]. (2020). Questions and answers on nitrosamines as impurities in human medicinal products. https://www.ema.europa.eu
3. Hites, R. A. (2017). Elements of environmental chemistry (2nd ed.). Wiley.
4. International Agency for Research on Cancer [IARC]. (2018). IARC monographs on the evaluation of carcinogenic risks to humans, Volume 114: Some chemicals present in industrial and consumer products, food, and drinking-water. https://monographs.iarc.who.int/
5. International Council for Harmonisation [ICH]. (2005). ICH Q2(R1): Validation of analytical procedures: Text and methodology. https://www.ich.org
6. International Council for Harmonisation [ICH]. (2017). ICH M7: Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. https://www.ich.org
7. Kumar, A., Gupta, R., & Srivastava, S. (2020). Recent advances in gas chromatography applications. Analytical Chemistry Letters, 10(1), 55–67. https://doi.org/10.1080/22297928.2020.1712880
8. Lurie, I. S., Weiss, J. A., & Hays, P. A. (2018). Recent advances in gas chromatography for the analysis of pharmaceuticals. Journal of Chromatography A, 1571, 172–182. https://doi.org/10.1016/j.chroma.2017.07.047
9. Rathore, A. S., Bhushan, B., & Yadav, S. (2020). Gas chromatography in the detection of genotoxic impurities: Regulatory perspectives. Pharmaceutical Technology, 44(3), 25–30.
10. Scott, R. P. W., & Bench, P. J. (2019). Advances in flow control systems for gas chromatography. Journal of Chromatographic Science, 57(5), 381–392.
11. Snyder, L. R., Kirkland, J. J., & Dolan, J. W. (2017). Introduction to modern liquid chromatography (3rd ed.). Wiley.
12. U.S. Food and Drug Administration [FDA]. (2020). Control of nitrosamine impurities in human drugs. https://www.fda.gov.